BioLife Solutions (STU:BJX1) ROCE % : -1.31% (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is BioLife Solutions ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. BioLife Solutions's annualized ROCE % for the quarter that ended in Mar. 2025 was -1.31%.

BioLife Solutions ROCE % Historical Data

The historical data trend for BioLife Solutions's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions ROCE % Chart

BioLife Solutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROCE %

Get a 7-Day Free Trial

-2.56

-8.57

-2.41

-6.50

-1.97

BioLife Solutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
ROCE %	Get a 7-Day Free Trial															-3.60	-7.71	-1.66	5.79	-1.31

BioLife Solutions ROCE % Calculation

BioLife Solutions's annualized ROCE % for the fiscal year that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2024 )		(A: Dec. 2023 )		(A: Dec. 2024 )
	=	-6.808	/	( ( (378.459 - 38.677)	+	(381.51 - 31.261) )	/ 2 )
	=	-6.808	/	( (339.782	+	350.249)	/ 2 )
	=	-6.808	/	345.0155
	=	-1.97 %

BioLife Solutions's ROCE % of for the quarter that ended in Mar. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2025 )		(Q: Dec. 2024 )		(Q: Mar. 2025 )
	=	-4.508	/	( ( (381.51 - 31.261)	+	(365.505 - 25.644) )	/ 2 )
	=	-4.508	/	( ( 350.249	+	339.861 )	/ 2 )
	=	-4.508	/	345.055
	=	-1.31 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

BioLife Solutions (STU:BJX1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

BioLife Solutions ROCE % Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (STU:BJX1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

BLFS:USA

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

BioLife Solutions Headlines

No Headlines